Find Academic Supervisors

• Immunology
• Translational Immunology
• Computational Immunology
• +4 more

Professor Mark Coles serves as Professor of Immunology and Lead for Industrial Strategy and Entrepreneurship at the Kennedy Institute of Rheumatology, University of Oxford, holding concurrent roles as Kennedy Trust Senior Research Fellow, Official Fellow at Reuben College, and Affiliate Faculty at the Wolfson Centre of Mathematical Biology. His interdisciplinary work bridges immunology, computational modeling, and translational research to accelerate therapies for immune-mediated inflammatory diseases. His academic journey began with a BSc in Microbiology from Cornell University (1992), followed by a PhD in Molecular and Cell Biology at UC Berkeley under David Raulet, and postdoctoral training with Dimitris Kioussis at the National Institute of Medical Research. At the University of York (2006-2017), he pioneered stromal immunology research and co-founded the York Computational Immunology Laboratory. Coles' research centers on stromal and systems immunology, with core expertise in stromal cell biology, inflammatory disease mechanisms, and mathematical modeling of immune responses. He champions 3Rs-based approaches (Replacement, Reduction, Refinement) to reduce animal testing through in silico models, integrating spatial single-cell biology with multi-scale computational frameworks to dissect immune function in human tissues. His 2025 publications reveal a cohesive research trajectory applying interdisciplinary methods across diverse disease contexts—from cardiac fibrosis and vaccine responses to arthritis pathogenesis and CAR-T cell therapy—unified by focus on stromal-immune crosstalk and quantitative modeling to identify therapeutic targets. Key honors include: Fellow of the Royal Society of Biology Kennedy Trust Senior Research Fellow As former Director of Graduate Studies (2017-2024) at the Kennedy Institute, Coles mentored numerous graduate students while co-leading major initiatives including the Arthritis Therapy Acceleration Program and Human Cell Atlas medicalization. His entrepreneurial impact spans three co-founded ventures: Simomics Ltd (in silico disease modeling), Lightox Ltd (phototherapy for oral cancer), and Mestag Therapeutics (fibroblast-targeted therapies for cancer/inflammation). He directs the Laboratory of Stromal and Systems Immunology and Oxford Mathematical Immunology Group, fostering collaborations with Christopher Buckley, Calliope Dendrou, and Eamonn Gaffney to develop Quantitative Systems Pharmacology models that translate mechanistic insights into patient therapies.

• Immunology
• Genomics
• Multiomics Analysis
• +3 more

Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.

Jessica WilliamsView profile

Assistant Professor

• Neuroimmunology
• Multiple Sclerosis
• Astrocyte Biology
• +5 more

Jessica Williams, PhD is an Assistant Professor in the Department of Neurosciences at the Cleveland Clinic Lerner Research Institute (LRI) with additional faculty appointments at Case Western Reserve University, Kent State University, and Cleveland State University. She serves as the Cleveland Clinic liaison for Kent State University and represents the Clinic on the Executive Council for the Brain Health Institute and the Biomedical Sciences Graduate Program Executive Committee. Education: Postdoctoral Fellowship in Neuroimmunology, Washington University School of Medicine (2017) Ph.D. in Immunology, The Ohio State University (2011) M.S. in Physiology, Purdue University (2006) B.S. in Biology/Chemistry, Lindenwood University (2004) Dr. Williams' research focuses on neuroimmune interactions during multiple sclerosis, particularly examining regional responses of CNS glia to immune stimuli and astrocyte-immune crosstalk. Her lab employs murine MS models, primary human and murine cell analyses, and MS patient lesion assessment to investigate cytokine-mediated neuroprotection and CNS repair mechanisms. Recent work highlights protective astrocyte functions mediated by traditionally deleterious cytokines. Analysis of her 15 most recent publications reveals consistent focus on neuroimmune crosstalk in MS, with increasing emphasis on astrocyte heterogeneity, cytokine signaling (particularly IFNγ), and novel therapeutic targets like immunoproteasomes. Key themes include regional CNS differences in immune responses, glial cell repair mechanisms, and translating basic findings into potential MS therapies. Scientific Awards: Lerner Research Institute Excellence in Education Award (2022) Mentor of the Year Award (2023) Dr. Williams actively mentors the next generation of scientists as evidenced by her CIMER Trained Mentor certification and the graduation of PhD student Brandon Smith. Her research is supported by significant funding from the NIH, National MS Society, W.M. Keck Foundation, Brain Health Research Institute, and Neurological and Vision Impact Area. She regularly serves on study sections for the NIH, National MS Society, and Department of Defense. The Williams Laboratory investigates the interplay between immune and central nervous systems during MS, with current projects examining cytokine-mediated neuroimmune crosstalk for CNS repair and regionally distinct glial responses to inflammation. The lab employs advanced techniques including murine MS models and primary human cell analyses to identify novel therapeutic pathways for MS patients.

Anil KumarView profile

Assistant Professor

• Molecular Virology
• Virus-host Interactions
• Innate Immune Response
• +3 more

Dr. Anil Kumar is an Assistant Professor in the Department of Biochemistry, Microbiology & Immunology at the University of Saskatchewan's College of Medicine. He specializes in molecular virology, focusing on positive-stranded RNA viruses and their interactions with host immune systems. His research employs high-throughput genetic screens and reverse genetics systems to identify host factors critical for viral infection. Education includes a BSc in Agricultural Sciences (1999, Kerala Agricultural University), MSc in Plant Pathology (2001, Indian Agricultural Research Institute), and PhD in Molecular Virology (2010, University of Heidelberg). Postdoctoral training included stints at the University of Heidelberg (2010–2013) and the University of Alberta (2014–2020). Research interests center on Eastern Equine Encephalitis virus (EEEV) and Enterovirus D68 (EV-D68). For EEEV, his lab investigates immune evasion mechanisms and host-virus protein interactions to identify therapeutic targets. For EV-D68, they study CNS invasion mechanisms and novel host dependency factors linked to acute flaccid myelitis (AFM). Recent work includes studies on SARS-CoV-2, uncovering roles for host proteins like Argonaute 2 in viral restriction. His lab integrates molecular biology, virology, and systems biology approaches, with a focus on translational research for antiviral drug development. Collaborations include work on respiratory syncytial virus (RSV) entry mechanisms and dengue virus replication regulation.

Caetano Reis e SousaView profile

Professor

• Immunology
• Infectious Disease
• Cancer Immunotherapy
• +3 more

Caetano Reis e Sousa is a Professor of Immunology at Imperial College London and Senior Group Leader/Assistant Research Director at the Francis Crick Institute. He leads the Immunobiology Laboratory, focusing on dendritic cell biology, immune responses to pathogens, and cancer immunotherapy. His research explores how dendritic cells detect pathogens and dying cells, triggering adaptive immunity. Key roles include investigating cross-presentation mechanisms, C-type lectin receptors (e.g., DNGR-1), and vaccine development strategies. Education: BSc (Hons) Biology from Imperial College London (1989), DPhil in Immunology from University of Oxford (1992). Postdoctoral training at NIH under Ron Germain. Career milestones include founding the Immunobiology Lab at CRUK London Research Institute (1998–2015) before joining the Crick. Awards & Recognition: Highly Cited Researcher (Thomson Reuters), BD Biosciences Prize (2002), Liliane Bettencourt Award (2008), Louis-Jeantet Prize (2017), Fellowships at Royal Society (2019), Academy of Medical Sciences (2006), and EMBO (2006). Named Officer of the Order of Sant'Iago da Espada (Portugal, 2009). Research Themes: Dendritic cell activation pathways, cross-presentation of tumor antigens, microbiome-cancer immunity links, and immune evasion mechanisms. Collaborations involve institutions like UCL, King's College London, and global health networks. Labs/Teams: Head of Immunobiology Lab at Crick, with expertise in immunology, cell biology, and virology. Facilities include Flow Cytometry, Genomics, and Light Microscopy cores. Active in pandemic response (e.g., SARS-CoV-2 testing initiatives).

Katherine J. FranzView profile

Professor

• Bioinorganic Chemistry
• Metal Homeostasis
• Antimicrobial Agents
• +4 more

Katherine J. Franz is a Professor of Chemistry at Duke University, affiliated with the Trinity College of Arts & Sciences and the Duke Cancer Institute. She holds a Ph.D. from MIT (2000) and a B.A. from Wellesley College (1995). Her research focuses on bioinorganic chemistry, particularly metal ion coordination in biological systems, with applications in antimicrobial therapies, cancer metallomics, and neurodegenerative diseases. Key projects include developing prochelators targeting fungal and bacterial pathogens, studying copper's role in antifungal drug efficacy, and designing light-activated metal complexes for controlled drug release. Dr. Franz has received numerous awards including the Camille Dreyfus Teacher-Scholar Award (2009), Sloan Research Fellowship (2008), and the NSF CAREER Award (2005). She leads a lab with 6 current students/mentees and has secured grants from NIH, NSF, and the US-Israel Binational Science Foundation. Her lab's work spans from fundamental metalloprotein studies to translational drug development, emphasizing interdisciplinary approaches in chemistry and biology. Education: Ph.D. in Chemistry, MIT, 2000 B.A. in Chemistry, Wellesley College, 1995 Research Interests: Metal homeostasis in pathogens, copper's role in antifungal resistance, prodrug design for targeted therapy, and mechanistic studies of metalloproteins. Grants: Tri-Institutional Molecular Mycology Training Program (NIH, 2024–2029) Duke PREP Biomedical Sciences Program (NIGMS, 2022–2027) Copper-Mucin Interaction Study (BSF, 2022–2026) Her lab's publications (n=15+ since 2020) highlight breakthroughs in prodrug selectivity, copper-induced protein toxicity, and histatin antifungal mechanisms. The Franz Lab actively collaborates with clinicians and computational scientists to advance therapeutic strategies addressing unmet medical needs in infectious diseases and cancer.

John F. Brooks IIView profile

Assistant Professor

• Circadian Biology
• Immunology
• Microbiome
• +7 more

John F. Brooks II is an Assistant Professor in the Department of Molecular Biology at Princeton University, where he leads the Brooks Lab. His research focuses on the circadian regulation of host-microbe dynamics, particularly how the circadian clock interfaces with the immune system to maintain gut microbiome harmony. Education: Ph.D., Northwestern University Feinberg School of Medicine, Walter S. and Lucienne Driskill Graduate Training Program in Life Sciences B.S., University of Michigan, Microbiology Research Interests: Dr. Brooks investigates how the circadian clock controls the rhythmic secretion of antimicrobial proteins (AMPs) in the small intestine and how persistent infections override these rhythms to sustain AMP production. His work integrates cell and molecular immunology, mouse genetics, and genomics to uncover mechanisms of circadian-immune crosstalk. This research has broad implications for disorders linked to circadian disruption, including obesity, diabetes, and chronic gut inflammation. Recent Publication Trends: His recent publications emphasize the coordination between microbial signals and host circadian rhythms in regulating innate immunity. Key themes include diurnal patterns in immune function, microbiota-driven immune modulation, and the physiological consequences of circadian misalignment in infection and disease. Scientific Awards: Pew Scholar in the Biomedical Sciences (2024) Advising and Grants: Dr. Brooks mentors graduate students and postdoctoral researchers, including Talia Akoh-Arrey and Urbashi Basu. His lab has received significant funding, notably the Pew Biomedical Scholars Award, supporting innovative research at the intersection of immunology, microbiology, and chronobiology. Labs and Teams: The Brooks Lab at Princeton employs interdisciplinary approaches to study host-microbe interactions. The team collaborates with experts in immunology and circadian biology, including Lora Hooper and Joseph Takahashi, to advance understanding of temporal regulation in immunity.

• Glycodrugs
• Protein-carbohydrate interactions
• Multivalency
• +7 more

Professor Roland J. Pieters is a distinguished academic at Utrecht University's Faculty of Science, where he serves as a full Professor in the Department of Chemical Biology and Drug Discovery. With over two decades of experience at the institution, he has progressed from Assistant Professor (1998) to Associate Professor (2005) and ultimately to Full Professor (2010-present). His research group is internationally recognized for groundbreaking work at the intersection of carbohydrate chemistry, chemical biology, and drug discovery, with particular emphasis on developing novel therapeutic approaches against bacterial infections and pathogenic mechanisms. Full Professor, Utrecht University (2010-present) Associate Professor, Utrecht University (2005-2010) Assistant Professor, Utrecht University (1998-2005) NWO Talent Post-doctoral Fellow, ETH-Zürich (1995-1996) Postdoctoral Researcher, University of Groningen (1996-1998) Professor Pieters earned his M.Sc. in Organic Chemistry from the University of Groningen in 1990, where he worked with Professor Ben Feringa, and completed his Ph.D. at MIT in 1995 under the supervision of Professor Julius Rebek Jr. His doctoral research focused on molecular recognition and template effects in bisubstrate systems, establishing the foundation for his lifelong interest in molecular interactions. Professor Pieters' research primarily centers on glycodrugs and the strategic interference with protein-carbohydrate interactions using multivalent systems of varying architectures. His laboratory has made significant contributions to understanding how rigid spacers in multivalent ligands can dramatically enhance binding affinity to target proteins, with applications against viral and bacterial adhesion proteins, toxins, galectins, and glycosidases. A particular focus has been on developing inhibitors for Pseudomonas aeruginosa lectin LecA, cholera toxin, influenza virus hemagglutinin, and more recently, SARS-CoV-2 spike protein interactions with host cell receptors. His group also pioneered the use of glyco- and peptide-microarrays for high-throughput screening of carbohydrate-protein interactions and drug discovery, particularly in the area of O-GlcNAcylation research. The publication record of Professor Pieters demonstrates consistent innovation in the field of multivalent carbohydrate-based therapeutics. His recent work (2020-2024) shows a strategic expansion into viral pathogenesis (particularly influenza and SARS-CoV-2), immune modulation through glycan recognition, and novel approaches to vaccine development. A notable trend is the increasing sophistication of multivalent architectures, moving from simple divalent systems to tetra- and hexavalent ligands with precisely engineered spatial arrangements. His research bridges fundamental chemical principles with practical therapeutic applications, maintaining strong connections to pharmaceutical development while advancing basic science understanding of carbohydrate-mediated biological processes. Professor Pieters' scientific achievements have been recognized with prestigious awards including a Fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW) in 1999 and a VICI personal grant from the Netherlands Organisation for Scientific Research (NWO) in 2008. These competitive awards reflect the significance and innovation of his research program. He has also served on editorial advisory boards, notably as Section Editor-in-Chief for Chemical Biology in the journal Molecules (2018-2022), contributing to the scholarly community through peer review and academic leadership. Fellowship of Royal Netherlands Academy of Sciences (KNAW), 1999 VICI, personal grant, NWO, 2008 Section Editor-in-Chief Chemical Biology for Molecules (2018-2022) Throughout his career, Professor Pieters has coordinated significant research projects including the EU project POLYCARB and secured competitive funding that has sustained his innovative research program. His laboratory has fostered numerous collaborations across Europe and internationally, creating a vibrant research environment that has trained many scientists now working in academia and industry. His research on multivalent carbohydrate systems represents a sustained intellectual contribution to chemical biology with direct relevance to developing new anti-infective strategies and therapeutic approaches. Professor Pieters leads an active research group within Utrecht University's Department of Chemical Biology and Drug Discovery, situated in the David de Wied Building. His laboratory maintains strong connections with other research groups both within Utrecht University and internationally, particularly in the fields of glycobiology, infectious diseases, and drug discovery. The research environment he has cultivated emphasizes interdisciplinary approaches, combining synthetic chemistry, biophysical analysis, and biological testing to address fundamental questions in carbohydrate-mediated biological processes with therapeutic applications.

Caitlin MullarkeyView profile

Associate Professor

• Immunology
• Virology
• Influenza Research
• +5 more

Caitlin Mullarkey is an Associate Professor in the Department of Biochemistry and Biomedical Sciences at McMaster University's Faculty of Health Sciences. She teaches across multiple undergraduate programs including Biochemistry, Biomedicine, and Health Sciences, with courses ranging from Cellular and Molecular Biology to Immunological Principles in Practice and Principles of Virology. Dr. Mullarkey's research focuses on immunology and virology with particular emphasis on influenza virus immunity, antibody-mediated responses, and vaccine development. Her work explores intricate mechanisms of antibody function including Fc-mediated effector functions, neutrophil responses to viral infection, and the role of broadly neutralizing antibodies. She also investigates innovative approaches to biomedical education through virtual laboratory simulations and online course development. Analysis of her publication record reveals a strong focus on influenza immunology, with particular expertise in antibody structure-function relationships, hemagglutinin stalk-specific antibodies, and Fc-mediated immune responses. Her work bridges basic immunological mechanisms with practical vaccine development approaches, demonstrating consistent contributions to understanding host-pathogen interactions and immune protection mechanisms. Scientific Awards: Equality of Opportunity Award from the Government of Ontario (2024) for developing and leading McMaster's Biochemistry and Biomedical Sciences Summer Scholars Program Dr. Mullarkey actively supervises undergraduate research through Senior Research Thesis and Senior Thesis courses, providing mentorship to students across multiple academic years. Her teaching portfolio demonstrates significant commitment to both foundational and advanced topics in biochemistry and immunology. Beyond formal teaching, she leads the Summer Scholars Program which provides full research scholarships to students who identify as Black, Indigenous, and/or 2SLGBTQIA+, addressing barriers to participation in STEM research through comprehensive support for training, mentorship, and living expenses. As Chair of the Biochemistry and Biomedical Sciences Summer Scholars Program, Dr. Mullarkey has graduated 17 diverse scholars in just two years, with many continuing research at McMaster and receiving competitive awards. The program, supported by McMaster's Global Nexus and Michael G. DeGroote Institute for Infectious Disease Research, exemplifies her commitment to creating inclusive research opportunities in biomedical sciences.

Xin LiView profile

Professor

• Plant Innate Immunity
• Molecular Mechanisms of Plant Defense
• Pathogen-Plant Interactions
• +5 more

Dr. Xin Li is a Professor at the University of British Columbia (UBC), affiliated with the Michael Smith Laboratories and the Department of Botany. She holds a Tier 1 Canada Research Chair in Plant Immunity and leads research on plant innate immunity mechanisms, focusing on molecular pathways in Arabidopsis thaliana. Her work explores how plants defend against pathogens through gene regulation, protein interactions, and signal transduction. Education: BSc in Genetics from Fudan University (1989), PhD in Plant Pathology from Oklahoma State University (1995), postdoctoral training at Duke University (1996-1999). Prior to UBC, she was a Scientist at Maxygen, Inc. (1999-2001). Research spans biochemistry, genomics, and proteomics, with a focus on regulatory components of plant disease resistance. Key areas include NLR immune receptors, salicylic acid signaling, and translational strategies for sustainable agriculture. Lab members include PhD students (e.g., Paul Kapos, Kevin Ao), MSc students (e.g., Nanbing Zhang), and postdocs (e.g., Tongjun Sun). The Li Lab collaborates internationally, notably through the PRoTECT training program funded by NSERC and DFG. Notable awards include the Tier 1 CRC nomination (2022) and grants supporting the PRoTECT initiative. Her research has led to over 70 peer-reviewed publications, advancing understanding of plant immunity and its applications in crop protection.

Xuan LiView profile

Research Fellow

• Cardiovascular Medicine
• Microtubule Cell Biology
• Inflammatory Diseases
• +3 more

Dr. Xuan Li is a British Heart Foundation (BHF) Senior Basic Science Research Fellow and Principal Investigator in Cardiovascular Health at the Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge. Her research focuses on microtubule dysfunction in inflammatory cardiovascular diseases, particularly investigating how microtubule regulation impacts inflammasome activation and cardiomyocyte contractility in heart failure and atherosclerosis. Her academic journey includes medical training in China, a CRUK-funded PhD in biochemistry at the University of Birmingham, postdoctoral research in microtubule cell biology as an MRC Career Development Fellow at the MRC-LMB Cambridge, and specialized cardiovascular medicine training at the University of Cambridge. She established her independent research group at Cambridge, pioneering multidisciplinary approaches to study microtubule function in cardiovascular cells. Dr. Li's research program centers on the role of microtubule-regulating kinases (particularly MARK4) in cardiovascular pathologies. Her group employs advanced methodologies including cardiovascular disease models (atherosclerosis, myocardial infarction, cardiomyopathy), primary cell culture of cardiomyocytes and immune cells, single-cell physiology using IonOptix systems, and cutting-edge microscopy techniques. Key discoveries include the identification of MARK4 as a critical regulator of inflammasome activation in atherosclerosis and microtubule detyrosination in ischemic heart failure. Her publication record demonstrates consistent focus on microtubule-cytoskeleton interactions in cardiovascular inflammation, with recent high-impact papers in Nature, Nature Communications, and Circulation Research revealing novel therapeutic targets for heart disease treatment through microtubule modulation. Scientific recognition includes: British Heart Foundation Senior Basic Science Research Fellowship MRC Career Development Fellowship Cancer Research UK PhD Studentship Dr. Li's group currently pursues four major research thrusts: elucidating microtubule dysfunction mechanisms in cardiovascular disease development, dissecting inflammation-microtubule interplay in pathogenesis, establishing human cardiomyocyte culture systems for microtubule studies, and translating basic findings into diagnostic and therapeutic applications for cardiovascular diseases. Her work bridges fundamental cell biology with clinical cardiology to develop innovative treatments targeting the microtubule cytoskeleton.

Moira WhyteView profile

Professor

• Respiratory medicine
• Inflammation
• Neutrophil biology
• +5 more

Moira Whyte serves as Sir John Crofton Professor of Respiratory Medicine and Head of Edinburgh Medical School at the University of Edinburgh, while directing the MRC University of Edinburgh Centre for Inflammation Research. Her leadership spans clinical academia and major research initiatives focused on respiratory pathophysiology. Her educational background includes a 1st Class B.Sc. (1981), M.B., B.S. (1984), and Ph.D. (1993) from the University of London, complemented by professional qualifications: M.R.C.P. (1987), F.R.C.P. (1998), and F.Med.Sci. (2005) from the Academy of Medical Sciences. Whyte's research centers on neutrophil biology, macrophage function, and hypoxia signaling pathways in respiratory diseases. Her work explores how oxygen-sensing mechanisms like HIF pathways regulate immune cell function in COPD, pulmonary fibrosis, and bacterial infections, with particular focus on cellular metabolism and inflammation resolution. Analysis of her 15 most recent publications reveals consistent focus on neutrophil and macrophage biology within respiratory diseases, with growing emphasis on metabolic regulation of immune responses. Her work bridges basic science (using zebrafish models) with clinical applications, particularly in COPD and pulmonary fibrosis. Her scientific recognition includes: 2014 OBE for Services to Respiratory Medicine 2014 Foundation Fellow of the European Respiratory Society 2005 Fellow, Academy of Medical Sciences 2002 Tudor Edwards Lecturer of the Royal College of Physicians 1994 Wellcome Trust Advanced Fellowship 1989 MRC Clinical Training Fellowship Whyte directs substantial research funding, including a £6.4M Wellcome Trust Clinical PhD Programme (ECAT-Plus) and multiple grants investigating macrophage function in COPD, hypoxia pathways in pulmonary fibrosis, and neutrophilic inflammation regulation. Her collaborative approach is evident in multi-institutional projects like the EME-TIPAC study on pulmonary fibrosis. As Director of the MRC Centre for Inflammation Research, she leads a multidisciplinary team investigating fundamental mechanisms of inflammation across multiple disease contexts, with particular strength in respiratory immunology and translational applications.

Junfang WuView profile

Professor

• Neurotrauma
• Neuropharmacology
• Neuroinflammation
• +7 more

Dr. Junfang Wu is a Professor in the Department of Anesthesiology and holds a secondary appointment in Neurobiology at the University of Maryland School of Medicine. She serves as Associate Director of UM-MIND (University of Maryland - Medicine Institute for Neuroscience Discovery), Director of the Anesthesiology Center for Neuroscience Research, and Vice-Chair for Translational Research in the Department of Anesthesiology. Her academic journey includes a BM in Medicine, MS in Pharmacology from Jiangxi Medical College, and PhD in Neuropharmacology from Nanjing Medical University, followed by postdoctoral training at China's Institute of Materia Medica and NIH. Research Focus: Neurotrauma, neuroinflammation, autophagy-lysosomal pathway, extracellular vesicles, Hv1/NOX2/ROS, TrkB.T1 Key Techniques: Rodent models of SCI/TBI, behavioral evaluations, EV characterization, quantitative imaging, molecular/cellular biology Dr. Wu's research explores the cellular and molecular mechanisms of neurological dysfunction following CNS trauma, with emphasis on autophagy-lysosomal disruption, microglial Hv1 channels, and EV-mediated neuroinflammatory signaling. Her 2025 Aging and disease study reveals age-dependent transcriptional changes post-anesthesia, while 2024 Brain, Behavior, and Immunity work demonstrates how SCI alters EV cargoes to drive brain neuroinflammation. Her team recently discovered that Hv1 proton channel ablation in microglia provides neuroprotection in SCI models. Her scientific contributions are recognized through the 2025 Matjasko Professorship in Anesthesiology Research. She has secured multiple NIH grants including: R01 NS145443 (2025-2030): cGAS signaling in brain trauma-induced neuroinflammation R01 AG077541 (2022-2027): TBI olfactory dysfunction and dementia progression 2RF1 NS094527 (2016-2027): Autophagy mechanisms in SCI R01 NS110825 (2020-2026): Hv1 channel in SCI/TBI Dr. Wu's laboratory personnel include Research Associates Yun Li and Zhuofan Lei, Post-doctoral Fellows Balaji Krishnamachary and Zihui Wang, Research Assistant Hui Li, and medical student Ruth Park. Her work spans from bench research on lysosomal damage to clinical implications for Alzheimer's disease-related dementia (AD/ADRD) and potential therapeutic strategies.

Kuo-Fen LeeView profile

Professor

• Molecular Neurobiology
• Nerve Regrowth
• Spinal Cord Injury
• +5 more

Kuo-Fen Lee, PhD is a Professor at the Salk Institute for Biological Studies, holding the prestigious Helen McLoraine Chair of Molecular Neurobiology. He leads the Clayton Foundation Laboratories for Peptide Biology, where his research focuses on nerve regeneration, spinal cord injury, and molecular mechanisms underlying neural development and neurodegenerative diseases. His work bridges basic neuroscience with potential therapeutic applications for conditions like ALS, paralysis, and Alzheimer's disease. Dr. Lee received his educational training from multiple prestigious institutions: a degree in Plant Pathology from National Taiwan University; an MS in Cancer Enzymology and Cell Differentiation from National Yang-Ming Medical College, Taiwan; a PhD in Endocrinology from Baylor College of Medicine, Houston; and completed his postdoctoral training at the Whitehead Institute for Biomedical Research. His primary research interests center on understanding why humans cannot regenerate damaged nerves while many other animals can. Dr. Lee has made significant discoveries regarding the p45 protein, which promotes nerve regrowth in mice but is absent in humans (who instead have p75, which inhibits nerve growth). His laboratory also studies neuregulin signaling, neuromuscular synapse formation, and the role of various proteins like nestin in neural development and maintenance. His work often employs mouse models to investigate spinal cord injury, pain pathways, and neurodegenerative conditions. Analysis of Dr. Lee's recent publications reveals a consistent focus on molecular neurobiology with particular emphasis on neural signaling pathways, synaptic maintenance, and nerve regeneration mechanisms. His research spans from basic molecular mechanisms to potential therapeutic applications, with increasing attention to pain pathways, Alzheimer's disease models, and the intersection of neuroscience with immunology and metabolism in recent years. As holder of the Helen McLoraine Chair of Molecular Neurobiology, Dr. Lee has received significant institutional recognition for his contributions to neuroscience. While specific awards aren't detailed in the provided text, his sustained funding and leadership position indicate substantial peer recognition in his field. Dr. Lee's research program involves extensive collaboration with other neuroscience laboratories, as evidenced by his numerous co-authored publications across various neuroscience subdisciplines. His work has been consistently funded, allowing for the maintenance of an active research laboratory focused on nerve regeneration and molecular neurobiology. The Clayton Foundation Laboratories for Peptide Biology serves as the primary research environment for Dr. Lee's team, where they investigate molecular mechanisms of nerve development, regeneration, and degeneration using advanced genetic, molecular, and cellular approaches. The laboratory maintains active research programs in multiple areas of neural signaling and development.

Ali NazmiView profile

Assistant Professor

• Nutritional Immunology
• Mucosal Immunology
• Host-Pathogen Interactions
• +3 more

Dr. Ali Nazmi is an Assistant Professor in the Department of Animal Sciences and the Food for Health Discovery Theme at The Ohio State University. He holds affiliations within the College of Food, Agricultural, and Environmental Sciences (CFAES). His research focuses on nutritional immunology, host-pathogen interactions in poultry and pigs, and the metabolic roles of intestinal immune cells. Nazmi obtained his B.Sc. in Poultry Production and M.Sc. in Poultry Breeding from Ain Shams University (Egypt), followed by a Ph.D. in Animal Biology from UC Davis (2017). He completed postdoctoral training in mucosal immunology at Vanderbilt University Medical Center before joining OSU in 2021. His recent work includes studies on intraepithelial lymphocytes in intestinal health, enteric disease resistance in poultry, and swine T cell biology. Key publications address mechanisms of necrotic enteritis in chickens, unconventional T cell subsets, and cytokine regulation in colitis models. Collaborations span avian immunology, swine immunology, and semen cryopreservation techniques. Education: B.Sc. (Ain Shams), M.Sc. (Ain Shams), Ph.D. (UC Davis) Postdoc: Vanderbilt University Medical Center (mucosal immunology) Key Research Themes: Nutritional Immunology, Mucosal Immunity, Avian/Porcine Health